Anti-Xa Levels in Critically Ill Patients Receiving Low-molecular-weight Heparin for Thromboprophylaxis in China

• Conditions: Anti-Xa; Critically Ill
• Interventions: Diagnostic Test: anti Xa level

• Registration Number: NCT03311984
• Lead Sponsor: Southeast University, China

Brief Summary

Critically ill Patients are at high risk to develop deep venous thrombosis. However, despite receiving of a standard dose of Low-molecular-weight Heparin（LMWH）, many patients still develop life-threatening embolism. The purpose of this study is to evaluate the anti-Xa levels of different dosing regimens of LMWH in critically ill patients in China.

Detailed Description

Not available

Study Timeline

• Study Start: 2017-08-15
• Status Verified: 2017-10
• Study First Submitted: 2017-10-06
• Study First Submitted QC: 2017-10-16
• Last Update Submitted: 2017-10-16
• Study First Posted: 2017-10-17
• Last Update Posted: 2017-10-17
• Primary Completion: 2018-03-30
• Study Completion: 2018-05-30

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 200

Inclusion Criteria

• Adult Critically ill patients

Exclusion Criteria

• Contraindication to use of LMWH. Intracranial bleeding/stroke, hematoma or bleeding disorder. Use Heparin anticoagulant therapy

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
LMWH q12h	anti Xa level	receiving Low-molecular-weight Heparin（LMWH）q12h
LMWH qd	anti Xa level	receiving Low-molecular-weight Heparin（LMWH）qd

Primary Outcome Measures

Name	Time	Method
Anti-Xa Levels	six months

Trial Locations

Locations (1)

Changde Wu; 🇨🇳 Nanjing, Jiangsu, China